1.28  -0.03 (-2.29%)		10-30 16:00
Open: 1.36 High: 1.42 Volume: 40,537		Pre. Close: 1.31 Low: 1.28 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	1.83	1-year :	2.06
Resists	First :	1.56	Second :	1.76
Pivot price	1.52
Supports	First :	1.24	Second :	1.03
MAs	MA(5) :	1.42	MA(20) :	1.56
	MA(100) :	3.35	MA(250) :	5.73
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	14.3	D(3) :	13.9
RSI	RSI(14): 31.1
52-week	High :	12.8	Low :	1.24

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SKYE ] has closed below the lower bollinger band by 10.2%. Bollinger Bands are 65.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.37 - 1.38	1.38 - 1.38
Low:	1.26 - 1.27	1.27 - 1.28
Close:	1.27 - 1.29	1.29 - 1.3

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Thu, 15 Oct 2026
TANG CAPITAL MANAGEMENT LLC Acquires 263,560 Shares of Skye Bios - GuruFocus

Mon, 17 Aug 2026
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ... - Yahoo Finance

Fri, 14 Aug 2026
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - GlobeNewswire

Fri, 14 Aug 2026
Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView

Fri, 14 Aug 2026
Skye and Redx form new entity with $125M to advance fibrosis assets - Fierce Biotech

Tue, 23 Jun 2026
Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	3 (M)
Held by Insiders	4.2 (%)
Held by Institutions	46.1 (%)
Shares Short	148 (K)
Shares Short P.Month	129 (K)

EPS	-10.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.11
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-95.1 %
Return on Equity (ttm)	-233.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-10.7
Qtrly Earnings Growth	0 %
Operating Cash Flow	-39 (M)
Levered Free Cash Flow	-19 (M)

PE Ratio	-0.13
PEG Ratio	0
Price to Book value	-11.69
Price to Sales	0
Price to Cash Flow	-0.15

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.